Objectives: Patient-reported outcomes (PROs) are important measures of efficacy in the context of clinical trials but are sometimes identified as time and resource intensive to study participants and site personnel. The objective of this research was to evaluate the amount of time that participants spend completing PROs via an electronic device in phase 2 and 3 clinical trials across several disease areas.
Methods: The electronic Clinical Outcome Assessment (eCOA) data were obtained from Johnson & Johnson clinical trials across various disease areas from 2016 to 2023. Data were acquired from internal and external sources including clinical trial sites and eCOA partners. In total, 82 trials were analyzed, containing data from 33,633 unique participants, and 1,083,994 measurements of completed electronic PRO instruments. After data cleaning, descriptive and multivariate analyses were performed. Electronic PRO completion time was examined in two ways: by time-per-item and time-per-instrument for each PRO.
Results: On average, participants spend about 16 s per item and an average of 2 min to complete a PRO instrument electronically. The average time to complete PRO instruments varied significantly by disease area and most eCOA were completed on study site tablets (68%) or personal handheld devices (31%).
Conclusions: Overall, patients spend an average of 16 s per item and 2 min per PRO instrument in clinical trial studies. PROs are a crucial component of clinical trial outcomes data and can be efficiently completed electronically by participants in clinical trials in a short amount of time.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s43441-025-00767-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Expectancy Effects, Failure of Blinding Integrity, and Placebo Response in Trials of Treatments for Psychiatric Disorders: A Narrative Review.
JAMA Psychiatry
March 2025
Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.
Importance: Expectancy effects are significant confounding factors in psychiatric randomized clinical trials (RCTs), potentially affecting the interpretation of study results. This narrative review is the first, to our knowledge, to explore the relationship between expectancy effects, compromised blinding integrity, and the effects of active treatment/placebo in psychiatric RCTs. Additionally, we present statistical and experimental approaches that may help mitigate the confounding impact of expectancy effects.
View Article and Find Full Text PDFGut Microbiota Modulation of Dementia Related Complications.
Aging Dis
March 2025
First Clinical Medical College, Heilongjiang University of Chinese Medicine, Harbin 150040, China.
Recent advances in microbial pathogen research have highlighted the potential of gut microbe-based microbial medicine. One of the most extensively studied biological pathways is the gut-brain axis, which has been shown to reverse neurological disorders. Evidence from animal-based studies of dysbiosis suggest complex behavioral changes, such as alterations in sociability and anxiety, can be modulated through gut microbiota.
View Article and Find Full Text PDFKinetic Energy Measured by 4D Flow Cardiac MRI in Evaluating Intraventricular Hemodynamics: A Systematic Review.
J Magn Reson Imaging
March 2025
Department of Radiology, Central Hospital of Dalian University of Technology, Dalian, People's Republic of China.
Unlabelled: Four-dimensional flow cardiovascular magnetic resonance (4D Flow cardiac MRI) is an advanced non-invasive imaging technology, and its derived kinetic energy (KE) blood flow parameters have been confirmed as a potential biomarkers for assessing ventricular hemodynamics. This review synthesizes details on the methodology, clinical significance, and current status of studies focused on quantifying KE parameters of the ventricle using 4D Flow cardiac MRI, providing an objective foundation for further exploration of the value of KE in cardiac diseases.
Study Type: retrospective.
Advances in Therapy of Adult Patients with Acute Lymphoblastic Leukemia.
Cells
March 2025
Department of Hematology and Medical Oncology, Advocate Lutheran General Hospital, Park Ridge, IL 60068, USA.
The landscape of adult acute lymphoblastic leukemia (ALL) is dramatically changing. With very promising results seen with novel immunotherapeutics in the setting of relapsed and refractory disease, the prospect of using these agents in first-line therapy has prompted the development of multiple clinical trials addressing this question. This review seeks to outline and expand the current standard of care, as well as new advances, in the treatment of adult patients with ALL and address future areas of research.
View Article and Find Full Text PDFInterleukin 24 Promotes Mitochondrial Dysfunction, Glucose Regulation, and Apoptosis by Inactivating Glycogen Synthase Kinase 3 Beta in Human Prostate Cancer Cells.
Cells
February 2025
Department of Biological Sciences, Herbert H. Lehman College, City University of New York, 250 Bedford Park Boulevard West, New York, NY 10468, USA.
Interleukin 24 (IL-24) is a tumor-suppressing protein currently in clinical trials. We previously demonstrated that IL-24 leads to apoptosis in cancer cells through protein kinase A (PKA) activation in human breast cancer cells. To better understand the mechanism by which IL-24 induces apoptosis, we analyzed the role of glycogen synthase kinase-3 beta (GSK3β), a highly conserved serine/threonine kinase in cancer cells and a downstream target of PKA.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!